AN2 Therapeutics (ANTX) Retained Earnings (2021 - 2026)

AN2 Therapeutics (ANTX) has reported Retained Earnings for 6 consecutive years, with -$5000.0 the latest figure, recorded in Q1 2026.

• In Q1 2026, Retained Earnings fell 110.42% year-over-year to -$5000.0; the TTM figure through Mar 2026 stood at -$5000.0 (down 110.42% YoY), while the FY2025 annual figure was -$241.0 million, down 17.09% from the prior year.
• Retained Earnings rose to -$5000.0 in Q1 2026 per ANTX's latest filing, from -$241.0 million in the prior quarter.
• Across five years, Retained Earnings topped out at $291.7 million in Q2 2025 and bottomed at -$241.0 million in Q4 2025.
• Historically, Retained Earnings has averaged $33.4 million across 5 years, with a median of -$27000.0 in 2024.
• Annual changes were most pronounced in 2022 — Retained Earnings plunged 1285.19% — and 2025, when it jumped 1080485.19%.
• AN2 Therapeutics' Retained Earnings stood at -$374000.0 in 2022, then soared by 74667.11% to $278.9 million in 2023, then plunged by 173.79% to -$205.8 million in 2024, then decreased by 17.09% to -$241.0 million in 2025, then soared by 100.0% to -$5000.0 in 2026.
• Business Quant data shows ANTX's Retained Earnings at -$5000.0 in Q1 2026, -$241.0 million in Q4 2025, and -$232.2 million in Q3 2025.